Theriva Biologics, Inc.
TOVX
$0.25
$0.014.52%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -2.40% | 54.23% | 66.60% | -201.99% | 2.77% |
| Total Depreciation and Amortization | -11.11% | -3.57% | 3.70% | 3.85% | -3.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -117.61% | 17.78% | -94.01% | 5,464.29% | -168.57% |
| Change in Net Operating Assets | 79.08% | -194.49% | 24.10% | -138.97% | 43.80% |
| Cash from Operations | 14.78% | 33.27% | 8.34% | 0.93% | -1.39% |
| Capital Expenditure | -- | 100.00% | -18.75% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | -18.75% | -- | -- |
| Total Debt Issued | -- | -55.88% | -40.35% | -95.93% | -- |
| Total Debt Repaid | -4,800.00% | 50.00% | 81.82% | 80.36% | -- |
| Issuance of Common Stock | -78.06% | 3,662.01% | -95.83% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 178.56% | -347.06% | -746.48% | -95.89% | -- |
| Cash from Financing | -54.29% | 5,814.86% | -102.17% | 121.71% | 43,785.71% |
| Foreign Exchange rate Adjustments | 25.00% | 54.72% | -241.94% | -133.33% | 175.61% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -75.14% | 220.38% | -323.78% | 228.98% | 66.90% |